Skip to Main Content

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS)

Conditions

Diseases of the Nervous System

Phase III

What is the purpose of this trial?

This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS. Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions. Participants will be randomized to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52.

  • Trial with
    Genentech Foundation for Biomedical Sciences
  • Start Date
    06/28/2016
  • End Date
    09/29/2018
Trial Image

For more information about this study, contact:

Lesa Moemeka

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/22/2018
  • Study HIC
    #1602017292